Ethanolic Extract of Nigella sativa Seeds Lacks the Chemopreventive Efficacy in the Post Initiation Phase of DMH-Induced Colon Cancer in a Rat Model

Wasfi Asfour, Sawsan Almadi, Lina Haffar

Department of Histopathology, College of Medicine, Damascus University, Damascus, Syria..
Department of Pharmacology and Toxicology, College of Pharmacy, Damascus University, Damascus, Syria.

DOI: 10.4236/pp.2013.42031                

Abstract

Nigella sativa, belonging to the Ranunculacea family, is a versatile phytochemical mine bestowed with multi-dimensional medicinal effects. The current study was performed to investigate the chemopreventive efficacy, if any, of the ethanolic extract of indigenous Nigella sativa seeds (ENS) and to evaluate its potentials on tumor progression during the initiation and post initiation phases of Dimethylhydrazine-induced colon carcinogenesis in a rat model. ENS treatment during the initiation phase unveiled chemopreventive effect manifested by significant reductions in tumor incidence, multiplicity and tumor volumes. Histopathological findings and modified Duke’s classification of tumors provided evidence that ENS, administered in the initiation phase, is capable of delaying progression, restricting invasion and attenuating aggressiveness of colon tumors. These results imply that ENS may be a promising candidate in the primary prevention of colon cancer. On the contrary, we demonstrated that ENS lacked chemopreventive and tumorigenesis inhibitory effects in the post initiation phase. We speculate that the chemopreventive effect of ENS might be due to the synergistic actions of various constituents present in the extract. However, extensive studies are warranted and more efforts need to be dedicated to fractionate, analyze and to further appraise the anticancer effect of ENS before any definitive conclusions can be drawn.

Keywords

Lack; Ethanolic Extract; Nigella sativa; Dimethylhydrazine; Post Initiation; Colon Cancer; Rat; Modified Duke’s Classification

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	J. Ferlay, F. Bray, P. Pisani and D. Parkin, “GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide,” IARC Cancer Base, Vol. 5, IARC Press, Lyon, 2004.
[2]	J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers and D. M. Parkin, “GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide,” IARC Cancer Base, Vol. 10, International Agency for Research on Cancer Press, Lyon, 2010. http://globocan.iarc.fr
[3]	Z. Msallati, A. El Jord and F. Al-Jerf, “Cancer Incidence in Syria, National,” Cancer Registry, Cancer Prevention Directorate, Ministry of Health, Damascus, 2009.
[4]	E. T. Hawk, A. Umar, J. L. Viner, “Colorectal Cancer Chemoprevention: An Overview,” Gastroenterology, Vol. 126, No. 5, 2004, pp. 1423-1447. doi:10.1053/j.gastro.2004.03.002
[5]	P. C. M. Jansen, “Spices, Condiments and Medical Plants in Ethiopia: Their Taxonomy and Agricultural Significance,” Center for Agricultural Publishing and Documentation, Addis Ababa, 1981, pp. 76-85.
[6]	S. I. Saad, “Classification of Flowering Plants,” 2nd Edition, The General Egyptian Book Co., Alexandria, 1975, pp. 412-413.
[7]	M. F. Ramadan, “Nutritional Value, Functional Properties and Nutraceuticals Applications of Black Cumin (Nigella sativa L.): An Overview,” International Journal of Food Science & Technology, Vol. 42, No. 10, 2007, pp. 12081218. doi:10.1111/j.1365-2621.2006.01417.x
[8]	K. E. El Tahir and D. Bakeet, “The Black Seed Nigella sativa Linnaeus—A Mine for Multi Cures: A Plea for Urgent Clinical Evaluation of Its Volatile Oil,” Review, Journal of Taibah University for Medical Sciences, Vol. 1, No. 1, 2006, pp. 1-19.
[9]	M. Abdel-Fattah, K. Matsumoto and H. Watanabe, “AntiNociceptive Effects of Nigella sativa Oil and Its Major Components in Mice,” European Journal of Pharmacology, Vol. 400, No. 1, 2000, pp. 89-97. doi:10.1016/S0014-2999(00)00340-X
[10]	T. El-Alfy, H. El-Fatatry and Toama, “Isolation and Structure Assignment of an Anti-Microbial Principle from the Volatile Oil Nigella sativa L.,” Pharmazia, Vol. 30, 1975, pp. 109-111.
[11]	M. N. Morsi, “Antimicrobial Effect of Crude Extracts of Nigella sativa on Multiple Antibiotics-Resistant Bacteria,” Acta Microbiologica Polonica, Vol. 49, No. 1, 2000, pp. 63-74.
[12]	A. Al-Hader, M. Aqel and Z. Hassan, “Hypoglycaemic Effects of the Volatile Oil of Nigella sativa,” Pharmaceutical Biology, Vol. 31, No. 2, 1993, pp. 96-100. doi:10.3109/13880209309082925
[13]	K. E. El Tahir, M. M. Ashour and M. M. Al-Harbi, “The Cardiovascular Actions of the Volatile Oil of the Black Seed (Nigella sativa) in Rats: Elucidation of the Mechanism of Action,” General Pharmacology: The Vascular System, Vol. 24, No. 5, 1993, pp. 1123-1131. doi:10.1016/0306-3623(93)90359-6
[14]	F. R. Dehkordi and A. F. Kamkhah, “Antihypertensive Effect of Nigella sativa Seed Extract in Patients with Mild Hypertension,” Fundamental & Clinical Pharmacology, Vol. 22, No. 4, 2008, pp. 447-452. doi:10.1111/j.1472-8206.2008.00607.x
[15]	M. Mahfouz, R. Abdel-Maguid and M. El-Dakhakhny, “The Effect of Nigellon Therapy on the Histaminopexic Power of Blood Sera Asthmatic Patients,” Arzneimittelforschung, Vol. 15, 1965, pp. 1230-1231.
[16]	M. H. Boskabady, N. Mohsenpoor and L. Takaloo, “Antiasthmatic Effect of Nigella sativa in Airways of Asthmatic Patients,” Phytomedicine, Vol. 17, No. 10, 2010, pp. 707-713. doi:10.1016/j.phymed.2010.01.002
[17]	R. Medinica, S. Mukerjee, T. Huschart and W. Corbitt, “Immunomodulatory and Anticancer Activity of Nigella sativa Plant Extract in Humans,” Proceedings of the American Association for Cancer Research Annual Meeting, San Francisco, 10-13 April 1994, p. A2865.
[18]	M. El Kadi, O. Kandil and A. M. Tabuni, “Nigella sativa and Cell Mediated Immunity,” Archives of AIDS Research, Vol. 1, No. 5, 1990, pp. 232-235.
[19]	P. J. Houghton, R. Zarka, B. De Las Heras and J. R. Hoult, “Fixed Oil of Nigella sativa and Derived Thymoquinone Inhibit Eicosanoid Generation in Leukocytes and Membrane Lipid Peroxidation,” Planta Medica, Vol. 61, No. 1, 1995, pp. 33-36. doi:10.1055/s-2006-957994
[20]	A. Mutabagani and S. A. El-Mahdy, “Study of the AntiInflammatory Activity of Nigella sativa L. and Thymoquinone in Rats,” Saudi Pharmaceutical Journal, Vol. 5, No. 2-3, 1997, pp. 110-113.
[21]	N. Chehl, G. Chipitsyna, Q. Gong, C. J. Yeo and H. A. Arafat, “Anti-Inflammatory Effects of the Nigella sativa Seed Extract, Thymoquinone, in Pancreatic Cancer Cells,” HPB (Oxford), Vol. 11, No. 5, 2009, pp. 373-381. doi:10.1111/j.1477-2574.2009.00059.x
[22]	S. M. Suboh, Y. Y. Bilto and T. A. Aburjai, “Protective Effects of Selected Medicinal Plants against Protein Degradation, Lipid Peroxidation and Deformability Loss of Oxidatively Stressed Human Erythrocytes,” Phytotherapy Research, Vol. 18, No. 4, 2004, pp. 280-284. doi:10.1002/ptr.1380
[23]	M. Burits and F. Bucar, “Antioxidant Activity of Nigella sativa Essential Oil,” Phytotherapy Research, Vol. 14, No. 5, 2000, pp. 323-328. doi:10.1002/1099-1573(200008)14:5<323::AID-PTR621>3.0.CO;2-Q
[24]	M. F. Ramadan, L. W. Kroh and J. T. Morsel, “Radical Scavenging Activity of Black Cumin (Nigella sativa L.), Coriander (Coriandrum sativum L.), and Niger (Guizotia abyssinica Cass.) Crude Seed Oils and Oil Fractions,” Journal of Agricultural and Food Chemistry, Vol. 51, No. 24, 2003, pp. 6961-6869. doi:10.1021/jf0346713
[25]	M. A. Randhawa and M. S. Alghamdi, “A Review of the Pharmaco-Therapeutic Effects of Nigella sativa,” Pakistan Journal of Medical Research, Vol. 41. No. 2, 2002, pp. 77-83.
[26]	M. J. Salomi, S. C. Nair and K. R. Panikkar, “Inhibitory Effects of Nigella sativa and Saffron (Crocus sativus) on Chemical Carcinogenesis in Mice,” Nutrition and Cancer, Vol. 16, No. 1, 1991, pp. 67-72. doi:10.1080/01635589109514142
[27]	N. J. Salomi, S. C. Nair, K. K. Jayawardhanan, C. D. Varghese and K. R. Panikkar, “Antitumour Principles from Nigella sativa Seeds,” Cancer Letters, Vol. 63, No. 1, 1992, pp. 41-46. doi:10.1016/0304-3835(92)90087-C
[28]	D. R. Worthen, O. A. Ghosheh and P. A. Crooks, “The in Vitro Anti-Tumor Activity of Some Crude and Purified Components of Blackseed, Nigella sativa L.,” Anticancer research, Vol. 18, No. 3, 1998, pp. 1527-1532.
[29]	N. El-Najjar, M. Chatila and H. Moukadem, “Reactive Oxygen Species Mediate Thymoquinone-Induced Apoptosis and Activate ERK and JNK Signaling,” Apoptosis, Vol. 15, No. 2, 2010, pp. 183-195. doi:10.1007/s10495-009-0421-z
[30]	H. Gali-Muhtasib, D. Kuester and C. Mawrin, “Thymoquinone Triggers Inactivation of the Stress Response Pathway Sensor CHEK1 and Contributes to Apoptosis in Colorectal Cancer Cells,” Cancer Research, Vol. 68, 2008, pp. 5609-5618. doi:10.1158/0008-5472.CAN-08-0884
[31]	M. Alhosin, A. Abusnina and M. Achour, “Induction of Apoptosis by Thymoquinone in Lymphoblastic Leukemia Jurkat Cells Is Mediated by a p73-Dependent Pathway which Targets the Epigenetic Integrator UHRF1,” Biochemical Pharmacology, Vol. 79, No. 9, 2010, pp. 12511260. doi:10.1016/j.bcp.2009.12.015
[32]	K. Womack, M. Anderson and M. Tucci, “Evaluation of Bioflavonoids as Potential Chemotherapeutic Agents,” Biomedical Sciences Instrumentation, Vol. 42, 2006, pp. 464-469.
[33]	L. R. Richards, P. Jones and J. Hughes, “The Physiological Effect of Conventional Treatment with Epigallocatechin-3-gallate, Thymoquinone, and Tannic Acid on the LNCaP Cell Line,” Biomedical Sciences Instrumentation, Vol. 42, 2006, pp. 357–362.
[34]	L. R. Richards, P. Jones and H. Benghuzzi, “A Comparison of the Morphological Changes Associated with Conventional and Sustained Treatment with Pigallocatechin-3-gallate, Thymoquinone, and Tannic Acid on LNCaP Cells,” Biomedical Sciences Instrumentation, Vol. 44, 2008, pp. 465-470.
[35]	S. M. K. Swamy and T. K. H. Benny, “Extraction, Isolation and Characterization of Anti-Tumor Principle, Alpha-Hederin, from the Seeds of Nigella sativa,” Planta Medica, Vol. 67, No. 1, 2001, pp. 29-32. doi:10.1055/s-2001-10628
[36]	H. Aboul-Enein and L. Abou-Basha, “Simple HPLC Method for the Determination of Thymoquinone in Black Seed Oil (Nigella sativa Linn.),” Journal of Liquid Chromatography, Vol. 18, No. 5, 1995, pp. 895-902. doi:10.1080/10826079508010400
[37]	K. M. Pozharisski, “Morphology and Morphogenesis of Experimental Epithelial Tumors of the Intestine,” Journal of the National Cancer Institute, Vol. 54, No. 5, 1975, pp. 1115-1135.
[38]	R. Peto, “Epidemiology, Multistage Models, and ShortTerm Mutagenicitytests,” In: H. H. Hiatt, et al., Eds., Origins of Human Cancer, Cold Spring Harbour Laboratories, New York, 1977, pp. 1403-1438.
[39]	V. B. Astler and F. A. Coller, “The Prognostic Significance of Direct Extension of Carcinoma of the Colon and Rectum,” Annals of Surgery, Vol. 139, No. 6, 1954, pp. 846-852. doi:10.1097/00000658-195406000-00015
[40]	M. A. Randhawa and M. S. Alghamdi, “Anticancer Activity of Nigella sativa (Black Seed)—A Review,” The American Journal of Chinese Medicine, Vol. 39, No. 6, 2011, pp. 1075-1091. doi:10.1142/S0192415X1100941X
[41]	S. M. Swamy and B. K. Tan, “Cytotoxic and Immunopotenciating Effects of Ethanolic Extract of Nigella sativa L. Seed,” Journal of Ethnopharmacology, Vol. 70, No. 1, 2000, pp. 1-7. doi:10.1016/S0378-8741(98)00241-4
[42]	E. I. Salim and S. Fukushima, “Chemopreventive Potential of Volatile Oil from Black Cumin (Nigella sativa L.) Seeds against Rat Colon Carcinogenesis,” Nutrition and Cancer, Vol. 45, No. 2, 2003, pp. 195-202. doi:10.1207/S15327914NC4502_09
[43]	S. Attoub, O. Sperandio, H. Raza and K. Arafat, “Thymoquinone as an Anticancer Agent: Evidence from Inhibition of Cancer Cells Viability and Invasion in Vitro and Tumor Growth in Vivo,” Fundamental and Clininal Pharmacology, 2012 (online). doi:10.1111/j.1472-8206.2012.01056.x
[44]	T. Yi, S. G. Cho, Z. Yi and X. Pang, “Thymoquinone Inhibits Tumor Angiogenesis and Tumor Growth through Suppressing AKT and ERK Signaling Pathways,” Molecular Cancer Therapeutics, Vol. 7, No. 7, 2008, pp. 1789-1796. doi:10.1158/1535-7163.MCT-08-0124
[45]	W. Asfour, S. Almadi and L. Haffar, “Thymoquinone Suppresses Cellular Proliferation, Inhibits VEGF Production and Obstructs Tumor Progression and Invasion in the Rat Model of DMH-Induced Colon Carcinogenesis,” Pharmacology & Pharmacy, Vol. 4, No. 1, 2013, pp. 7-17. doi:10.4236/pp.2013.41002
[46]	G. M. Ganea, S. O. Fakayode and J. N. Losso, et al., “Delivery of Phytochemical Thymoquinone Using Molecular Micelle Modified Poly(D,L lactide-co-glycolide) (PLGA) Nanoparticles,” Nanotechnology, Vol. 21, No. 28, 2010, Article ID: 285104. doi:10.1088/0957-4484/21/28/285104
[47]	A. M. Ahmed, E. M. Al-Olayan, M. A. M. Aboul-Soud and A. A. Al-Khedhairy, “The Immune Enhancer, Thymoquinone, and the Hope of Utilizing the Immune System of Aedes Caspius against Disease Agents,” African Journal of Biotechnology, Vol. 9, No. 21, 2010, pp. 31833195.
[48]	I. O. Farah and R. A. Begum, “Effect of Nigella sativa (N. sativa L.) and Oxidative Stress on the Survival Pattern of MCF-7 Breast Cancer Cells,” Biomedical Sciences Instrumentation, Vol. 39, No. 1, 2003, pp. 359-364.
[49]	M. A. El-Aziz, H. A. Hassan and M. H. Mohamed, et al., “The Biochemical and Morphological Alterations Following Administration of Melatonin, Retinoic Acid and Nigella sativa in Mammary Carcinoma: An Animal Model,” International Journal of Experimental Pathology, Vol. 86, No. 6, 2005, pp. 383-396. doi:10.1111/j.0959-9673.2005.00448.x
[50]	S. R. Samarakoon, P. B. Thabrew, D. Galhena, De-Silva and K. H. Tennekoon, “A Comparison of the Cytotoxic Potential of Standardized Aqueous and Ethanolic Extracts of a Polyherbal Mixture Comprised of Nigella sativa (Seeds), Hemidesmus Indicus (Roots) and Smilax Glabra (Rhizome),” Pharmacognosy Research, Vol. 2, No. 6, 2010, pp. 335-342. doi:10.4103/0974-8490.75451
[51]	S. Rooney and M. F. Ryan, “Modes of Action of Alpha-Hederin and Thymoquinone, Active Constituents of Nigella sativa, against HEP-2 Cancer Cells,” Anticancer Research, Vol. 25, No. 6B, 2005, pp. 4255-4259